Scientists map immune cells in rare cancer to boost treatment

NCT ID NCT07561190

Recruiting now Knowledge-focused Sponsor: Azienda USL Reggio Emilia - IRCCS Source: ClinicalTrials.gov ↗

First seen May 07, 2026 · Last updated May 07, 2026

Summary

This study looks at the immune system inside malignant pleural mesothelioma, a rare and hard-to-treat cancer. Researchers will analyze tumor samples from 300 patients to understand why immunotherapy helps some people but not others. The goal is to find clues that could lead to more effective treatments in the future. Participants will not receive any experimental therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Azienda Ospedaliera Universitaria Luigi Vanvitelli, Napoli
RECRUITING

Naples, Italy

Contact Email: •••••@•••••
Azienda Ospedaliera Universitaria Policlinico Rodolico San Marco di Catania
RECRUITING

Catania, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••
Azienda USL IRCCS di Reggio Emilia
RECRUITING

Reggio Emilia, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
RECRUITING

Roma, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

MALIGNANT PLEURAL MESOTHELIOMA (MPM)